EASL)

Final results of the IDEAL study, the first large, randomized, clinical study comparing the leading therapies for chronic hepatitis C, were presented today at the 43rd Annual Meeting of the European Association for the Study of the Liver , providing important insights that may help guide clinical practice for physicians worldwide treating this serious and potentially life-threatening disease.
From: biz.yahoo.com